Q3 Asset Management Eli Lilly & CO Transaction History

Q3 Asset Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	SELL	$525.19 - $619.13 $95,059 - $112,062	-181 Reduced 5.04%	3,408 $1.99 Million
Q3 2023 Nov 03, 2023	BUY	$434.7 - $599.3 $1.56 Million - $2.15 Million	3,589 New	3,589 $1.93 Million
Q4 2022 Feb 02, 2023	BUY	$321.55 - $374.67 $950,823 - $1.11 Million	2,957 New	2,957 $1.08 Million
Q4 2021 Jan 25, 2022	SELL	$224.85 - $279.04 $610,917 - $758,151	-2,717 Closed	0 $0
Q3 2021 Oct 29, 2021	BUY	$221.6 - $272.71 $602,087 - $740,953	2,717 New	2,717 $627,000

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Q3 Asset Management, based on Form 13F filings with the SEC.

Stay updated on Q3 Asset Management with notifications on news.